Forecasting cholesterol management - End of the statin gold rush?

Journal of Managed Care Pharmacy

Volumn 12, Issue 6, 2006, Pages 479-485

  Crownover, Brian K ^a   Curtiss, Frederic R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; COLESTYRAMINE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; MK 0524; NICOTINIC ACID; NICOTINIC RECEPTOR BLOCKING AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; GENERIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; EDITORIAL; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MANAGED CARE; PATIENT CARE; PRACTICE GUIDELINE; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DRUG THERAPY; DYSLIPIDEMIA; ECONOMICS; FORECASTING; HEALTH INSURANCE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY; DRUGS, GENERIC; DYSLIPIDEMIAS; FORECASTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MANAGED CARE PROGRAMS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 34547454226     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.6.479     Document Type: Editorial

References (50)

1. Simvastatin (Zocor) [prescribing information from the product label]. Drug Facts and Comparisons (Clinisphere version, ISBN 1-57439-036-8). St. Louis, MO: Wolters, Kluwer Health, Inc.; May 2006. Accessed June 25, 2006.
2. Lovastatin (Mevacor) [prescribing information from the product label]. Drug Facts and Comparisons (Clinisphere version, ISBN 1-57439-036-8). St. Louis, MO: Wolters, Kluwer Health, Inc.; May 2006. Accessed June 25, 2006.
3. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74(7):667-73.
4. Atorvastatin calcium (Lipitor) [prescribing information from the product label]. Drug Facts and Comparisons (Clinisphere version, ISBN 1-57439-036-8). St. Louis, MO: Wolters, Kluwer Health, Inc.; June 2006. Accessed July 12, 2006.
5. Evans RT, Amusa G, Gandhi D, Kranson DB. PFE, MRK, SGP, AZN: Proprietary cholesterol market research. Bernstein Res Call. September 8, 2004.
6. Verispan, Scott-Levin SPA. Top 200 brand drugs by retail dollars in 2002. Drug Top. April 7, 2003:53.
7. Adams C. Consumer group asks FDA to strengthen warnings on cholesterol lowering drugs. Wall Street Journal. August 21, 2001:A2
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106:3143-421. NIH publication no. 02-5215, September 2002. Available at: http://www.nhlbi.nih.gov/ guidelines/cholesterol/atp3full.pdf. Accessed July 2, 2006.
9. Quilliam BJ, Perez E, Andros V, Jones P. Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. J Manag Care Pharm. 2004;10(3):244-50.
10. The statin wars: why AstraZeneca must retreat [editorial]. Lancet. 2003;362(9393):1341.
11. Evans RT, Gandhi D, Kranson DB. PFE: Net Lipitor US pricing, and how it compares to Crestor. Bernstein Res Call. February 2, 2004.
12. Data search performed April 5, 2004, of the data warehouse of a national pharmacy benefits manager representing approximately 500,000 beneficiaries of small employer drug benefit plans for pharmacy claims with dates of service from January 1, 2004, through March 31, 2004.
13. Hay JW. Evaluating the cost-effectiveness of statins. J Manag Care Pharm. 2004;10(1):79-81.
14. Nissen SE, Nicholls SJ, Sipahi I., writing for the ASTEROID investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-65.
15. Ohsfeldt RL. Challenges in evaluating the cost-effectiveness of statins. J Manag Care Pharm. 2004;10(1):81-82.
16. Winslow R. For Bristol-Myers, challenging Pfizer was a big mistake. In rare head-to-head study, Lipitor beats Pravachol at reducing heart risk. Wall Street Journal. March 9, 2004::A1, A8.
17. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
18. Paradis JM, LeLorier J. Intensive versus moderate lipid lowering with statins after acute coronary syndrome [letter]. N Engl J Med. 2004;351:715.
19. Cannon CP, Braunwald E. Intensive versus moderate lipid lowering with statins after acute coronary syndrome [letter]. N Engl J Med. 2004;351:716-17.
20. Winslow R. Lipitor prescriptions surge in wake of big study. Wall Street Journal. March 18, 2004:D4.
21. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352: 1425-35.
22. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease - is it time to shift our goals? N Engl J Med. 2005;352:1483-84.
23. Auer J, Lamm G, Eber B. Intensive lipid lowering with atrovastatin in coronary disease [letter]. N Engl J Med. 2005;353:93.
24. Cannon CP, Murphy SA, Braunwald E. Intensive lipid lowering with atrovastatin in coronary disease [letter]. N Engl J Med. 2005;353:93-94.
25. Southern W. Intensive lipid lowering with atrovastatin in coronary disease [letter]. N Engl J Med. 2005;353:95.
26. Nissen SE, Tuzcu EM, Schoenhagen P, et al., for the REVERSAL investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80.
27. Widimsky J. The ASTEROID trial presented in Atlanta at the ACC Congress 2006. High-dose rosuvastatin leads to regression of coronary atherosclerosis. Available at: http://www.servier.com/pro/cardiologie/pdfs/Wid48ang.asp. Accessed July 3, 2006.
28. Winslow R. New prescription for Zocor users. Wall Street Journal. June 17-18, 2006:A2.
29. Evans RT, Amusa G, Kranson DB, Parsons A. US drugs: Crestor likely to outgrow its dangerous image, pressuring prices - an update on adverse event rates. BernsteinResearch. June 6, 2006.
30. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363: 757-67.
31. Curtiss FR. Methods to attain optimal outcomes with lipid-lowering drug therapy. J Manag Care Pharm. 2004;10(3):267-70.
32. Price for 90 units of Zocor 40 mg tablets. Available at: www.drugstore.com. Accessed July 2, 2006.
33. Brett AS, Meilof JF, Uitdehaag BMI, Fruchter O. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000;343:1894-96.
34. Extended-release niacin (Niaspan) [prescribing information from the product label]. Drug Facts and Comparisons (Clinisphere version, ISBN 1-57439-036-8). St. Louis, MO: Wolters, Kluwer Health, Inc.; May 2006. Accessed June 25, 2006.
35. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 2006;332:752-760.
36. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and prevention and the American Health Association. Circulation. 2003;107:499-511.
37. Ridker PM, Koenig W, Fuster V, et al. C-reactive protein and coronary heart disease. N Engl J Med. 2004;351:295-97.
38. Evans RT, Kranson DB. US drugs: how secure is torcetrapib's lead? A high level overview of the HDL pipeline. BernsteinResearch. June 7, 2006.
39. van der Steeg WA, Kuivenhoven JA, KLerks AH, Boekholdt SM, Hovingh GK, Kastelein JJ. Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol. 2004;15(6):631-36.
40. Evans RT, Amusa G, Kranson DB, Parsons A. US drugs: LDL-lowering is a commodity: the money's in HDL. BernsteinResearch. April 4, 2006.
41. ClinicalTrials.gov identifier: NCT00134173 - A coronary IV US study to compare torcetrapib/atorvastatin to atorvastatin alone in subjects with coronary heart disease. Available at: http://www.clinicaltrials.gov/ct/show/NCT00134173. Accessed June 26, 2006.
42. Brookes L. Phase 2 studies with torcetrapib/atorvastatin combination. Medscape coverage of the American Heart Association Scientific Sessions, November 13-16, 2005, Dallas, Texas. Available at: http://www.medscape.com/ viewarticle/518571. Accessed July 17, 2006.
43. NHANES III data files. Available at: http://www.cdc.gov/nchs/about/major/ nhanes/nh3data.htm. Accessed June 26, 2006.
44. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilatation in mice and humans. Proc Natl Acad Sci. 2006;103(17):6682-87.
45. Merck's report to shareholders 2005. Available at: http://www.merck.com/ finance/annualreport/ar2005/pdf/Merck_2005_Editorial_Section.pdf. Accessed July 2, 2006.
46. ClinicalTrials.gov identifier: NCT00289900 - Lipid efficacy and safety in patients with mixed hyperlipidemia. Available at: http://www.clinicaltrials. gov/ct/show/NCT00289900;jsessionid=A3B351FC8F6B92AD2FAC5E585AFEDC3A?order=9. Accessed June 26, 2006.
47. ClinicalTrials.gov identifier: NCT00269217 - A multicenter, randomized. double-blind, "factorial" design study to evaluate the lipid-altering efficacy and safety of coadministered MK0524A + simvastatin tablets in patients with primary hypercholesterolemia or mixed hyperlipidemia. Available at: http://www.clinicaltrials.gov/ct/show/NCT00269217. Accessed July 2, 2006.
48. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95-104.
49. Avorn J. Torcetrapid and atorvastatin - should marketing drive the research agenda? N Engl J Med. 2005;325:2573-76.
50. Shear CL, Hirsch RL, Avorn J. Torcetapib and atorvastatin [letter]. N Engl J Med. 2006;353:1527-29.